Uricosuric drugs: The once and future therapy for hyperuricemia?

Current Opinion in Rheumatology

Volumn 26, Issue 2, 2014, Pages 169-175

  Bach, Mary H ^a   Simkin, Peter A ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

ATP binding cassette transporter G2; glucose transporter 9; probenecid; URAT1; uricosuric

Indexed keywords

ATP-BINDING CASSETTE TRANSPORTERS; DRUG DISCOVERY; ENZYME INHIBITORS; GLUCOSE TRANSPORT PROTEINS, FACILITATIVE; GOUT; HUMANS; HYDROCHLOROTHIAZIDE; HYPERURICEMIA; KIDNEY TUBULES, PROXIMAL; NEOPLASM PROTEINS; ORGANIC ANION TRANSPORTERS; ORGANIC CATION TRANSPORT PROTEINS; PROBENECID; URIC ACID; URICOSURIC AGENTS; XANTHINE OXIDASE;

EID: 84894027217     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0000000000000035     Document Type: Review

References (42)

1. Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: The National Health and Nutrition Examination Survey 2007-2008. Arthritis Rheum 2011; 63:3136-3141
2. Lawrence RC, Felson DT, Helmick CG, et al., for the National Arthritis Data Workgroup. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: Part II. Arthritis Rheum 2008; 58:26-35
3. Johson RJ, Segal MS, Srinivas T, et al. Essential hypertension, progressive renal disease and uric acid: A pathogenetic link? J Am Soc Nephrol 2005; 16:1909-1919
4. Martinon F, Petrilli V, Mayor A, et al. Gout-Associated uric acid crystals activate the NALP3 inflammasome. Nature 2006; 440:237-241
5. Sautin YY, Johnson RJ. Uric acid: The oxidant-Antioxidant paradox. Nucleosides Nucleotides Nucleic Acids 2008; 27:608-619
6. Gagliardi AC, Miname MH, Santos RD. Uric acid: A marker of increased cardiovascular risk. Atherosclerosis 2009; 202:11-17
7. George R, Keenan R. Genetics of hyperuricemia and gout: Implications for the present and future. Curr Rheumatol Rep 2013; 15:309
8. Reginato A, Mount D, Yang I, Choi H. The genetics of hyperuricaemia and gout. Nat Rev Rheumatol 2012; 8:610-621
9. Brondino CD, Romao JM, Moura I, Moura JJ. Molybdenum nad tungsten enzymes: The xanthine oxidase family. Curr Opin Chem Biol 2006; 10:109-114
10. Schlesinger N. New agents for the treatment of gout and hyperuricemia: Febuxostat, puricase, and beyond. Curr Rheumatol Rep 2010; 12:130-134
11. Maesaka JK, Fishbane S. Regulation of renal urate excretion: A critical review. Am J Kidney Dis 1998; 32:917-933
12. Perez-Ruiz F, Calabozo M, Erauskin GG, et al. Renal underexcretion of uric acid is present in patients with apparent high urinary uric acid output. Arthritis Care Res 2002; 47:610-613
13. Scott JT, Holloway VP, Glass HI, Arnot RN. Studies of uric acid pool size and turnover rate. Ann Rheum Dis 1969; 28:366-373
14. Simkin PA. Uric acid excretion in patients with gout. Arthr Rheum 1979; 22:98-99
15. Perez-Ruiz F, Calabozo M, Garcia Erauskin G, et al. Renal underexcretion of uric acid is present in patients with apparent high urinary uric acid output. Arthr Rheum 2002; 47:610-613
16. Kimiyoshi I, et al. Decreased extra-renal urate excretion is a common cause of hyperuricemia. Nat Commun 2012; 3:1-7
17. Lee M, Graham G, Williams K, Day R. A benefit-risk assessment of benzbromarone in the treatment of gout. Drug Safety 2008; 31:643-665
18. Reinders MK, van Roon EN, Jansen TL, et al. Efficacy and tolerability drugs in gout: A randomized controlled trial of benzbromarone verus probenecid after failure of allopurinol. Ann Rheum Dis 2009; 68:51-56
19. Stocker SL, Williams KM, McLachlan AJ, et al. Pharmacokinetic and pharmacodynamics interaction between allopurinol and probenecid in healthy subjects. Clin Pharmacokinet 2008; 47:111-118
20. Reinders M, van Roon E, Houtman P, et al. Biochemical effectiveness of allopurinol and allopurinol-probenecid in previously benzbromarone-Treated gout patients. Clin Rheumatol 2007; 26:1459-1465
21. Enomoto A, Kimura H, Chairoungdua A, et al. Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature 2002; 417:447-452
22. Burckhardt G. Drug transport by organic anion transporters (OATs). Pharmacol Ther 2012; 136:106-130
23. Li S, Sanna S, Maschio A, et al. The GLUT9 gene is associated with serum uric acid levels in Sardinia and Chianti cohorts. PLoS Genet 2007; 3:e194
24. Bannasch D, Safra N, Young A, et al. Mutations in the SLC2A9 gene cause hyperuricosuria and hyperuricemia in the dog. PLoS Genet 2008; 4:e1000246
25. Sorensen L. Role of the intestinal tract in the elimination of uric acid. Arth Rheum 1965; 8:694-706
26. Haimeur A, Conseil G, Deeley RG, Cole SP. The MRP-related and BCRP/ ABCG2 multidrug resistance proteins: Biology, substrate specificity and regulation. Curr Drug Metab 2004; 5:21-53
27. Maatsuo H, Takada T, Ichida K, et al. Common defects of ABCG2, a highcapacity urate exporter, cause gout: A function-based genetic analysis in a Japanese population. Sci Transi Med 2009; 1:5rall
28. So A, Thorens B. Uric acid transport and diseases. J Clin Invest 2011; 120:1791-1799
29. Bobulescu I, Moe O. Renal transport of uric acid: Evolving concepts and uncertainties. Adv Chronic Kidney Dis 2012; 19:358-371
30. Yamamoto T, Moriwaki Y, Takahashi S, et al. Effects of pyrazinamide, probenecid, and benzbromarone on renal excretion of oxypurinol. Ann Rheum Dis 1991; 50:631-633
31. Rizwan AN, Burckhardt G. Organic anion transporters of the SLC22 family: Biopharmaceutical, physiological, and pathological roles. Pharm Res 2007; 24:450-470
32. Anzai N, Ichida K, Jutabha P, et al. Plasma urate level is directly regulated by a voltage-driven urate efflux transporter URATv1 (SLC2A9) in humans. J Biol chem 2008; 283:26834-26838
33. Yeh L, Shen Z, Kerr B, et al. RDEA594: A potent URAT1 inhibitor without affecting other important renal transporters, OAT1 and OAT3 [abstract]. Ann Rheum Dis 2009; 68 (Suppl 3); 320
34. Crittenden D, Pillinger M. New Therapies for Gout. Annu Rev Med 2013; 64:325-337
35. Burns CM, Wortmann RL. Gout therapeutics: New drugs for an old disease. Lancet 2011; 377:165-177
36. Tan PK, Hyndman D, Liu S, et al. Lesinurad (RDEA594), a novel investigational uricosuric agent for hyperuricemia and gout, blocks transport of uric acid induced by hydrochlorothiazide [abstract]. Ann Rheum Dis 2011; 70 (Suppl 3); 187
37. Lesinurad and Allopurinol Combination Extension Study in Gout, Sponsor: Ardea Biosciences, Inc. Lesinurad and Febuxostat Combination Extension Study in Gout, Sponsor: Ardea Biosciences, Inc. Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors (LIGHT), Sponsor: Ardea Biosciences, Inc. ClinicalTrials.gov: Http://clinicaltrials.gov/ct2/results? term=lesinurad&Search=Search. [Accessed 7 January 2014]
38. Perez-Ruiz F, Sundy J, Krishnan E, et al. Efficacy and safety of lesiurad (RDEA594), a novel uricosuric agent, given in combination with allopurinol in allopurinol-refractory gout patients: Randomized, double-blind, placebocontrolled, Phase 2B study [abstract]. Ann Rheum Dis 2011; 70 (Suppl 3); 104
39. Fleischmann R, Shen Z, Yeh L-T, et al. Lesinurad (RDEA594), a novel uricosuric agent, in combination with febuxostat shows significant additive urate lowering effects in gout patients with 100% response achieved for all combination dose regimens [abstract]. Ann Rheum Dis 2011; 70 (Suppl 3); 188
40. Miner J, Tan P. RDEA3170 a novel high affinity URAT1 inhibitor binds to central domain within URAT1. Ann Rheum Dis 2012; 71:446
41. Mandal A, Emerling D, Serafini T. Tranilast inhibits urate transport mediated by URAT1 and GLUT9. American College of Rheumatology Annual Scientific Meeting. ACR Poster Session A; Session: Metabolic and Crystal Arthropathies-Therapeutics and Outcomes I: Monday, November 8, 2010, Atlanta, GA, 2010
42. Takahashi S, Moriwaki Y, Yamamoto T, et al. Effects of combination treatment using antihyperuricaemic agents with fenofibrate and/or losartan on uric acid metabolism. Ann Rheum Dis 2003; 62:572-575